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bjectives The purpose of this study was to evaluate the risk of stent thrombosis (ST), clinical out-
omes, and the beneﬁts of extended clopidogrel use after drug-eluting stent (DES) implantation.
ackground Data are limited regarding uniform evaluation of ST and the inﬂuence of clopidogrel
ontinuation beyond 12 months on late events after DES treatment.
ethods We identiﬁed 7,221 patients who received DES implantation (n  3,160) or bare-metal
tent (BMS) implantation (n  4,061), and compared long-term adverse outcomes. Additionally,
,851 patients with DES surviving 12 months without major events were analyzed according to clo-
idogrel continuation.
esults The adjusted-risk of overall ST was similar in the 2 groups. After 1 year, however, DES pa-
ients showed a higher risk of ST; deﬁnite/probable (hazard ratio [HR]: 3.55, 95% conﬁdence interval
CI]: 1.26 to 9.99). The adjusted-risk of death (HR: 0.60, 95% CI: 0.46 to 0.79), death/myocardial in-
arction (HR: 0.63, 95% CI: 0.49 to 0.81), and target lesion revascularization (HR: 0.32, 95% CI: 0.24 to
.43) were signiﬁcantly lower in the DES group than in the BMS group. Continuing clopidogrel be-
ond 12 months was not associated with a reduced risk for ST (HR: 0.54, 95% CI: 0.07 to 4.23), death
HR: 1.20, 95% CI: 0.55 to 2.66), or death/myocardial infarction (HR: 1.16, 95% CI: 0.56 to 2.42) after
ES implantation.
onclusions As compared with BMS, DES showed a similar risk of overall ST, but a higher risk of
ery late ST. The rates of death, death/myocardial infarction, and target lesion revasuclarization
ere signiﬁcantly lower in the DES group. Clopidogrel continuation beyond 1 year did not appear
o reduce ST and clinical events after DES implantation. (J Am Coll Cardiol Intv 2008;1:494–503)
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495ased on clinical trials, the use of drug-eluting stents (DES)
as been associated with a significant decrease in restenosis
nd subsequent revascularization (1–3). The application of
ES has rapidly extended to the “real-world” population
ith more complicated clinical and lesion subsets (4–6).
oncerns have increased, however, about the long-term
afety of these DES platforms (7,8). In particular, DES
ave been associated with a higher risk of late stent
hrombosis (ST) compared to bare-metal stents (BMS) (9),
phenomenon not recognized in the initial clinical studies
wing to few events and limited durations of follow-up
10,11). Furthermore, premature discontinuation of thien-
pyridine was associated with a marked increase in the risk
f ST (12,13). The advisory panel of the U.S. Food and
rug Administration (FDA) recommended dual antiplate-
et therapy for at least 12 months after DES implantation
14).
However, there have been limited data applying uniform
efinitions for the safety profiles of these devices in routine
ractice. Also, the role of extended use of clopidogrel
eyond 12 months after DES implantation was uncertain.
e, therefore, evaluated the long-term safety of DES and
he influence of long-term continuation of clopidogrel on
ate events in an unselected, real-world population.
ethods
tudy population and procedures. This study included
onsecutive patients who underwent coronary artery stent
mplantation at 2 academic hospitals in Korea between
anuary 3, 1998, and February 28, 2006. The DES has been
dopted as the default treatment for percutaneous coronary
ntervention (PCI) since February 2003 at Asan Medical
enter, Seoul, and since May 2003 at Asan Medical Center,
angNeung. The choice of the specific type of DES (i.e.,
irolimus-eluting stent [Cypher, Cordis, Johnson & John-
on, Miami Lakes, Florida] or paclitaxel-eluting stent
Taxus, Boston Scientific, Natick, Massachusetts]) was left
o the physician’s discretion. Patients who underwent cor-
nary brachytherapy were excluded. Patients who received
oth a BMS and at least 1 DES at the same or different
imes were regarded as those with DES. All patients were
rescribed clopidogrel (loading dose, 300 or 600 mg) or
iclopidine (loading dose, 500 mg) plus aspirin before or
uring PCI. After the procedure, aspirin was continued
ndefinitely for all patients. Patients were prescribed clopi-
ogrel for at least 6 months, regardless of DES type (13).
reatment beyond this duration was at the discretion of the
hysician. Patients receiving BMS were prescribed clopi-
ogrel or ticlopidine for at least 1 month.
This study was approved by the local Ethics Committees
t Asan Medical Center, Seoul and GangNeung, and
ritten informed consent was obtained from all patients forhe use of clinical and PCI data. futcome variables and deﬁnitions. The end points of the
tudy were ST, death (all-cause, cardiac, or noncardiac),
yocardial infarction (MI), the composite of death or MI,
he composite of cardiac death or MI, and target lesion
evascularization. Stent thrombosis was assessed by the
cademic Research Consortium (ARC) definitions (14)
nd was classified by the level of certainty (definite, proba-
le, or possible) and by the timing of the event (early [0 to
0 days], late [31 days to 1 year], or very late [1 year]).
efinite ST was defined as an angiographically or patho-
ogically confirmed thrombus, along with ischemic symp-
oms or signs. Probable ST was defined as any unexplained
eaths within 30 days or acute MI of the target vessel
erritory without angiographic evidence. Possible ST in-
luded any unexplained deaths more than 30 days. All
eaths were considered cardiac unless an unequivocal non-
ardiac cause could be established. The diagnosis of acute
I was established in the presence of ischemic symptoms
nd cardiac enzyme elevation (creatine kinase-myocardial
and elevation 3 or creatine kinase elevation 2 the
pper limit of normal value)
15). Target lesion revasculariza-
ion was defined as revascular-
zation for a stenosis within the
tent or within the 5-mm borders
djacent to the stent. During the
djudication of outcomes, subse-
uent events occurring after re-
eated revascularization were in-
luded in the analysis. All clinical
utcomes of interest were adjudi-
ated by independent clinicians.
linical follow-up and data veri-
cation. Baseline clinical and
CI data were recorded into the dedicated database of each
nstitution by independent research personnel. Clinical
ollow-up was performed by office visit or telephone contact
t 1, 6, and 12 months after the procedure, and every 6
onths thereafter. Detailed information on antiplatelet
herapy was collected at each follow-up period for patients
reated with DES, as previously reported (13). Briefly, at the
ime of follow-up contact, patients were asked to provide a
edication list, especially regarding antiplatelet therapy. In
ases with discontinuation, detailed information (time and
eason for stopping) was obtained. Also, in cases of uncer-
ainty, general practitioners, referring cardiologists, and
atients were contacted as necessary.
To make the clinical follow-up of the 2 sequential cohorts
f patients (BMS and DES) comparable and reduce
ollow-up bias, clinical outcomes were censored at 3 years in
oth groups.
For validation of complete follow-up data, information
bout vital records was obtained through March 31, 2007,
Abbreviations
and Acronyms
ARC  Academic Research
Consortium
BMS  bare-metal stent(s)
CI  confidence interval
DES  drug-eluting stent(s)
HR  hazard ratio
MI  myocardial infarction
PCI  percutaneous
coronary intervention
ST  stent thrombosisrom the National Registration System of the Ministry of
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496overnment Administration and Home Affairs in Korea
sing a personal identification number. Also, data regarding
ehospitalization for follow-up MI were obtained from the
ospital Disease Code Registration System (categorized
ccording to the International Classification of Diseases-
0th Revision), which was merged for reimbursement in the
ealth Insurance Review Agency in Korea.
tatistical methods. Continuous variables were compared
ith the t test or Wilxocon rank sum test, and categorical
ariables were compared with the chi-square test or Fisher
xact test as appropriate. Cumulative event curves were
enerated using the Kaplan-Meier method and compared
Table 1. Baseline Clinical and Procedural Characteristics
Variable (n
Age (yrs) 6
Male 2
Diabetes mellitus
Hypertension 1
Current smoker
Hypercholesterolemia
Previous myocardial infarction
Previous coronary angioplasty
Previous coronary artery bypass graft
Renal failure
Acute coronary syndrome 1
Multivessel disease 1
Left ventricular ejection fraction (%) 5
Treated lesions, n
Vessels treated
Left anterior descending artery 2
Left circumﬂex artery
Right coronary artery 1
Left main coronary artery
Coronary graft
Lesion characteristics
ACC/AHA type B2 or C lesion 3
Bifurcation lesion
Restenotic lesion
Ostial lesion
Chronic total occlusion
Procedural characteristics
Direct stenting without pre-dilation
Intervention with intravascular ultrasound guidance 2
Maximal balloon pressure (atm) 1
Balloon-to-vessel ratio
Number of stents per patient
Total stent length per patient (mm) 4
Average stent diameter per patient (mm)
Glycoprotein IIb/IIIa inhibitors
Data are mean SD or n (%).
ACC/AHA American College of Cardiology/American Heart Association classification; BMS by the log rank test. Univariate and multivariable Cox Aroportional hazards models were used to examine the
ssociation of stent type with the risks of clinical events (16).
dditionally, selection bias for the choice of stent was
xamined with the use of a propensity model (17). The
ropensity scores were estimated without regard to out-
omes, using a multiple logistic-regression model including
ll the variables listed in Table 1 (18). This score ranged
rom 0.01 to 0.99, and the c statistic for the propensity score
odel was 0.87, indicating a strong discrimination. The
ndividual propensity score was incorporated into Cox
roportional hazards regression models as a covariate as well
s stent group to calculate the adjusted hazard ratios (HR).
160)
BMS
(n  4,061) p Value
10.3 59.2 10.1 0.001
0.5) 2,903 (71.5) 0.38
7.4) 835 (20.6) 0.001
0.6) 1,674 (41.2) 0.001
9.1) 1,642 (40.4) 0.001
4.0) 1,469 (36.2) 0.001
.4) 304 (7.5) 0.004
7.2) 373 (9.2) 0.001
.7) 65 (1.6) 0.002
.5) 82 (2.0) 0.13
1.8) 2,932 (72.2) 0.001
9.0) 1,656 (40.8) 0.001
8.8 59.2 9.6 0.001
1 5,702
9.3) 2,840 (49.8) 0.64
6.1) 928 (16.3) 0.76
7.1) 1,643 (28.8) 0.06
.8) 264 (4.6) 0.001
.6) 27 (0.5) 0.31
4.3) 3,250 (57.0) 0.001
6.3) 602 (10.6) 0.001
.6) 175 (3.1) 0.001
0.6) 427 (7.5) 0.001
.6) 217 (3.8) 0.001
6.2) 378 (6.6) 0.001
4.5) 2,676 (46.9) 0.001
3.9 12.8 3.8 0.001
0.2 1.1 0.1 0.001
1.1 1.4 0.7 0.001
31.0 26.6 15.1 0.001
0.7 3.4 0.9 0.001
.9) 232 (5.7) 0.001
al stent(s); DES drug-eluting stent(s).DES
 3,
0.5
,229 (7
865 (2
,599 (5
920 (2
759 (2
297 (9
544 (1
84 (2
80 (2
,637 (5
,865 (5
8.4
4,49
,216 (4
721 (1
,219 (2
307 (6
28 (0
,338 (7
732 (1
251 (5
475 (1
251 (5
727 (1
,897 (6
5.9
1.3
1.9
8.0
3.2
93 (2lso, the propensity scores were grouped into quintiles, and
H
o
p
p
w
u
e
a
c
s
1
t
u
s
t
f
A
f
f
c

p
I
R
B
2
w
(
(
2
4
t
o
3
t
w
s
m
a
s
l
h
t
S
D
p
[
I
h
g
S
s
r
fi
D
g
r
t
nterven
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 1 , N O . 5 , 2 0 0 8
O C T O B E R 2 0 0 8 : 4 9 4 – 5 0 3
Park et al.
Clinical Outcomes and Thrombosis After DES
497R was compared across quintiles. To evaluate very late
ccurring events, a landmark analysis was performed with a
re-specified landmark time point at 12 months (19). A new
ropensity score for DES versus BMS at the landmark point
as incorporated for each analysis.
To determine the association between extended contin-
ation of dual antiplatelet therapy beyond 1 year and late
vents among patients receiving DES, we used a landmark
nalysis based on continuing clopidogrel at last follow-up
ontact beyond 1 year. Patients who received DES and
urvived without MI or revascularization during the initial
2 months were included in this analysis. A Cox propor-
ional hazards model and a propensity score analysis were
sed to determine whether the long-term outcomes differed
ignificantly between patients taking clopidogrel and pa-
ients not taking clopidogrel beyond 1 year after controlling
or the patient’s risks (17,20). In addition, we calculated
alen-Nelson estimates of the cumulative hazard function
or patients on a regimen of double antiplatelet therapy and
or patients who discontinued thienopyridine therapy at a
ertain point in time.
All p values were 2-sided, and a probability value of
0.05 was considered significant. Statistical analysis was
erformed using SPSS version 12.0 for Windows (SPSS
nc., Chicago, Illinois).
esults
aseline characteristics. From February 2003 to February
006, a total of 3,160 patients (4,491 lesions) were treated
ith 6,171 DES at the 2 institutions, with 2,513 patients
80%) receiving sirolimus-eluting stents and 647 patients
Table 2. Unadjusted and Adjusted Hazard Ratios of Stent Thrombosis for U
Outcome
Rates (%)* Crude
Outcome DES BMS
Hazard Ratio
(95% CI) p
ARC deﬁnite
Overall at 3 yrs 1.0 0.9 1.10 (0.67–1.81)
1 yr after PCI 0.5 0.7 0.64 (0.34–1.19)
1–3 yrs after PCI 0.5 0.1 4.17 (1.54–11.29)
ARC deﬁnite or probable
Overall at 3 yrs 1.3 1.3 0.97 (0.63–1.49)
1 yr after PCI 0.5 1.0 0.53 (0.30–0.93)
1–3 yrs after PCI 0.7 0.2 3.64 (1.60–8.27)
Any ARC criteria
Overall at 3 yrs 2.5 1.9 1.30 (0.94–1.80)
1 yr after PCI 1.1 1.3 0.83 (0.54–1.27)
1–3 yrs after PCI 1.4 0.6 2.70 (1.60–4.57) 
*Outcome rates were derived from Kaplan-Meier curves. †Adjusted for all variables listed in Table 1
ARC Academic Research Consortium; CI confidence interval; PCI percutaneous coronary i20%) receiving paclitaxel-eluting stents. During 1998 and t003, before the adoption of DES as the default strategy,
,061 patients (5,702 lesions) received 5,867 BMS. When
he follow-up period was truncated at 3 years, mean length
f follow-up was 30.5  9.0 months in the DES group and
3.7  6.7 in the BMS group.
Baseline and procedural characteristics according to stent
ype are summarized in Table 1. As compared with patients
ho received BMS, patients who received DES were
ignificantly older and had a higher prevalence of diabetes
ellitus, hypertension, and a history of MI, coronary
ngioplasty, or bypass surgery. Also, patients with DES had
ignificantly lower mean ejection fractions and were more
ikely to have multivessel disease. Patients treated with DES
ad more complex lesions and procedural characteristics
han did patients with BMS.
tent thrombosis. During the 3 years, 66 patients in the
ES group (definite: 27 [41%], probable: 7 [11%], and
ossible: 32 [48%]) and 77 in the BMS group (definite: 35
45%], probable: 15 [20%], and possible: 27 [35%]) had ST.
n the DES group, 9 patients (14%) had early ST, 26 (39%)
ad late ST, and 31 (47%) had very late ST. In the BMS
roup, 29 patients (38%) had early ST, 25 (32%) had late
T, and 23 (30%) had very late ST.
Table 2 and Figure 1 summarize the risk of ST based on
tent type. In a crude and risk-adjusted analysis, the overall
ate of ST was similar in the two groups, whereas after the
rst year, the incidence of ST was more common in the
ES group than in the BMS group. This finding is
raphically presented in Figure 1, which shows that event
ates for patients with DES increase more steeply over time
han they do for patients with BMS. For each ARC criteria,
DES Compared With BMS in Entire Study Population
Multivariable Adjusted† Adjusted for Propensity
Hazard Ratio
(95% CI) p Value
Hazard Ratio
(95% CI) p Value
1.20 (0.64–2.26) 0.56 1.11 (0.58–2.09) 0.76
0.71 (0.32–1.57) 0.39 0.64 (0.29–1.42) 0.27
4.83 (1.50–15.57) 0.01 4.35 (1.32–14.30) 0.02
0.97 (0.55–1.71) 0.91 1.07 (0.60–1.91) 0.90
0.63 (0.30–1.31) 0.21 0.58 (0.28–1.21) 0.15
3.29 (1.18–9.17) 0.02 3.55 (1.26–9.99) 0.02
1.21 (0.80–1.83) 0.38 1.20 (0.79–1.84) 0.39
0.86 (0.50–1.49) 0.59 0.86 (0.49–1.51) 0.60
2.25 (1.16–4.36) 0.02 2.28 (1.17–4.43) 0.02
tion; other abbreviations as in Table 1.se of
Value
0.71
0.16
0.01
0.88
0.03
0.002
0.11
0.38
0.001
.he adjusted HR for very late ST across cohort quintiles was
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498onsistently higher in patients receiving DES compared to
atients receiving BMS.
eath, MI, and revascularization. During the 3 years of
ollow-up, 351 patients died (111 in the DES group and
40 in the BMS group) and 123 had MI (41 in the DES
roup and 82 in the BMS group). Table 3 and Figure 2
ummarize clinical events according to stent type. In a crude
nd multivariable adjusted analysis, mortality rate was sig-
ificantly lower in the DES group than in the BMS group.
he adjusted risks of death/MI and cardiac death/MI were
lso significantly lower in the DES group.
In the landmark analysis after 1 year, the rates of all-cause
nd noncardiac mortality were consistently lower in the
ES group than in the BMS group, whereas there was no
ifference in risk of cardiac death. The adjusted risk of
eath/MI in the DES group was lower after 1 year, whereas
he risk of cardiac death/MI after 1 year did not significantly
iffer between the 2 groups.
During the 3 years of follow-up, target lesion revascular-
zation was performed in 208 patients receiving DES and in
78 receiving BMS (8.1% vs. 15.0%, p  0.001). In the
ropensity score adjusted Cox regression analysis, the ad-
usted risk of target lesion revascularization was significantly
ower in the DES group (HR: 0.32, 95% CI: 0.24 to 0.43;
 0.001).
ong-term use of clopidogrel and outcomes after DES im-
lantation. Among patients receiving DES, the mean du-
ation of clopidogrel use was 11.8  8.0 months. Among
,873 eligible patients who received DES and survived the
rst 12 months without nonfatal MI and revascularization,
etailed information about clopidogrel treatment was avail-
ble for 2,851 patients (99.2%). Baseline and procedural
haracteristics according to continuation of clopidogrel at
he time of last follow-up are summarized in Table 4. More
atients continuing clopidogrel were older and had diabetes,
history of angioplasty or bypass surgery, renal failure, and
ultivessel disease, and presented with an acute coronary
yndrome. Also, procedural characteristics were more com-
lex for patients taking clopidogrel than for patients not
aking clopidogrel at last follow-up.
Among 467 patients taking clopidogrel at last follow-up
eyond 1 year, ST occurred in 3 patients (0.6%; definite: 2
0.4%] and definite or probable: 2 [0.4%]). In 2,384 patients
ot taking clopidogrel, ST occurred in 28 patients (1.2%;
efinite: 10 [0.4%] and definite or probable: 14 [0.6%]).
he median interval from clopidogrel discontinuation to the
ccurrence of ST was 12.7 months (interquartile range 6.9
o 21.8 months).
Table 5 summarizes ST and clinical events based on
ontinuing clopidogrel at last follow-up. In a crude analysis
nd multivariable analysis after adjusting confounders and
ropensity, there was no significant association between
lopidogrel continuation and outcomes. Figure 3 representsFigure 1. Kaplan-Meier Curves of Cumulative Incidence of Stent Thrombosis
Kaplan-Meier curves showing the cumulative incidence of stent thrombosis
over 3 years according to Academic Research Consortium (ARC) deﬁnitions:he association between the timing of clopidogrel discon-
t
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499inuation and the risk of ST among the overall population.
lthough the prevalence of ST was higher among patients
ot taking clopidogrel before 1 year, the incidence of ST
as similar after 1 year.
iscussion
n this study, we found that the overall rates of ST were not
ignificantly different for patients receiving DES versus
MS. However, DES was associated with a small but
ignificant increase of very late ST. In addition, DES was
ssociated with lower rates of death, death or MI, and repeat
evascularization. Continuing clopidogrel beyond 1 year did
ot seem to be associated with reduced risks of subsequent
T and clinical events after DES implantation.
Pooled analyses of clinical trials showed no evidence for
n increase in mortality or MI, and inconsistent evidence for
n increased risk of late thrombosis with DES compared
ith BMS (21–24). A large observational study from
weden, however, found evidence for an increased risk of
Table 3. Unadjusted and Adjusted Hazard Ratios of Clinical Outcomes for U
Outcome
Rates (%)* Crude
Outcome DES BMS
Hazard Ratio
(95% CI) p Va
Death (all causes)
Overall at 3 yrs 4.2 5.9 0.68 (0.54–0.84) 0.
1 yr after PCI 1.8 2.9 0.62 (0.45–0.85) 0.
1–3 yrs after PCI 2.4 3.1 0.74 (0.54–1.00) 0.
Cardiac death
Overall at 3 yrs 2.1 2.5 0.83 (0.60–1.14) 0.
1 yr after PCI 1.1 1.7 0.68 (0.45–1.01) 0.
1–3 yrs after PCI 0.9 0.9 1.18 (0.70–1.98) 0.
Noncardiac death
Overall at 3 yrs 2.1 3.4 0.59 (0.43–0.80) 0.
1 yr after PCI 0.6 1.2 0.54 (0.32–0.92) 0.
1–3 yrs after PCI 1.5 2.2 0.61 (0.42–0.90) 0.
MI
Overall at 3 yrs 1.5 2.1 0.76 (0.52–1.09) 0.
1 yr after PCI 0.7 1.4 0.51 (0.31–0.84) 0.
1–3 yrs after PCI 0.8 0.7 1.33 (0.77–2.31) 0.
Death or MI
Overall at 3 yrs 5.3 7.3 0.71 (0.58–0.86) 0.
1 yr after PCI 2.4 3.8 0.61 (0.47–0.81) 0.
1–3 yrs after PCI 3.0 3.6 0.82 (0.62–1.08) 0.
Cardiac death or MI
Overall at 3 yrs 3.3 4.0 0.83 (0.64–1.07) 0.
1 yr after PCI 1.7 2.7 0.65 (0.47–0.90) 0.
1–3 yrs after PCI 1.6 1.4 1.25 (0.83–1.87) 0.
*Outcome rates were derived from Kaplan-Meier curves. †Adjusted for all variables listed in Table 1
MImyocardial infarction; other abbreviations as in Tables 1 and 2.eath, or the composite of death or MI associated with DES ifter 6 months (25). In the present study, the 3-year rate of
T was similar in the DES and BMS groups, but there were
ignificant increases in very late ST associated with DES,
till raising concerns about the long-term safety.
Recent studies have used all-cause mortality as a surrogate
linical marker for late ST with DES (25,26). However,
oncardiac mortality accounted for more than 50% of
ll-cause mortality in other studies (27,28) and in our
esults. Also, death from ST in these studies accounted for
bout 10% of all-cause mortality (22). Therefore, to repre-
ent the biological and clinical relevance of infrequent
hrombosis, these clinical outcomes may need to be suffi-
iently defined and classified (29). In contrast to a recent
tudy reporting an increased rate of noncardiac mortality
ith DES relative to BMS (28), we found that noncardiac
ortality was significantly lower among patients with DES.
hen assessing the specific cause of noncardiac mortality,
e found that the risk of noncardiac death due to ischemic
ascular causes (ischemic stroke or other arterial embolism)
as lower for patients receiving DES than for those receiv-
DES Compared With BMS in the Entire Study Population
Multivariable Adjusted† Adjusted for Propensity
Hazard Ratio
(95% CI) p Value
Hazard Ratio
(95% CI) p Value
0.57 (0.43–0.75) 0.001 0.60 (0.46–0.79) 0.001
0.51 (0.32–0.80) 0.003 0.53 (0.34–0.82) 0.005
0.64 (0.45–0.92) 0.02 0.65 (0.46–0.93) 0.02
0.66 (0.42–1.03) 0.07 0.66 (0.42–1.02) 0.06
0.65 (0.36–1.19) 0.16 0.63 (0.35–1.16) 0.14
0.74 (0.38–1.43) 0.37 0.74 (0.39–1.40) 0.35
0.50 (0.35–0.73) 0.001 0.55 (0.38–0.79) 0.001
0.37 (0.18–0.76) 0.006 0.42 (0.21–0.82) 0.01
0.59 (0.38–0.92) 0.02 0.60 (0.39–0.93) 0.02
0.66 (0.41–1.05) 0.08 0.66 (0.42–1.05) 0.08
0.56 (0.29–1.05) 0.07 0.54 (0.29–1.02) 0.06
0.92 (0.46–1.86) 0.82 0.98 (0.49–1.93) 0.94
0.62 (0.48–0.79) 0.001 0.63 (0.49–0.81) 0.001
0.55 (0.37–0.80) 0.002 0.54 (0.37–0.79) 0.001
0.71 (0.51–0.98) 0.047 0.72 (0.52–0.99) 0.046
0.72 (0.51–1.00) 0.05 0.70 (0.50–0.97) 0.04
0.65 (0.41–1.03) 0.07 0.61 (0.39–0.97) 0.04
0.89 (0.54–1.49) 0.67 0.89 (0.54–1.46) 0.64se of
lue
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500nding may have been due, at least in part, to the extended
uration of clopidogrel treatment with DES. Also, the
nchecked paradigm shifts in general health care for indi-
idual patients over time might have been related to the
ifference in noncardiac mortality.
In contrast to previous studies (25,28), our study showed
hat the adjusted risk of death and death/MI were signifi-
antly lower in the DES group compared to the BMS
roup. These findings are consistent with recent results of
arge registries (30,31). Given that the risk of ST was similar
p to 1 year, significant decreases of in-stent restenosis,
hich could present as acute MI (32,33), and repeat
evascularization, which could lead to subsequent thrombo-
is and cardiac mortality (24), with DES may contribute to
he reduced risk of death or MI. Also, the rapid changes
ithin cardioprotective drugs such as statin and increased or
xtended use of clopidogrel could be responsible for these
ifferences.
In our study, the cumulative incidence of ST or mortality
as relatively lower than it was in recent reports from large
egistries (25,34). These discrepancies may be partially
xplained by differences in patient populations, lesion char-
cteristics, interventional practice, and ethnic groups.
Recent study suggested that the prolonged use of clopi-
ogrel was significantly associated with a reduced risk for
eath or MI in patients treated with DES (26). In contrast,
ur study showed that continuing clopidogrel beyond 1 year
as not associated with decreased risks of ST and clinical
vents. These findings are similar to those of other investi-
ators, who have suggested that discontinuation of clopi-
ogrel beyond 6 months after DES implantation was not
elated to subsequent risk of ST (35). The lack of random-
zation regarding discontinuation of thienopyridine therapy
t a certain time point and the low number of events that
ccurred more than 12 months after the procedure may
eaken the power to make a firm statement about the safety
f thienopyridine discontinuation during long-term follow-
p. Nonsignificant trends toward lower event rates (any
RC criteria) were seen among patients continuing clopi-
ogrel after 12 months; these trends might have been
ignificant with a larger cohort of patients. However, the
ime interval (median 12.7 months) between clopidogrel
iscontinuation and thrombosis might be too long to
peculate on the cause and effect of discontinuation on very
ate thrombosis. Therefore, considering the risk-benefit
atio of long-term use of clopidogrel, our findings warrant
urther investigation and should be confirmed or refuted
hrough large, randomized clinical trials with long-term
ollow-up.
tudy limitations. Although we used an unselected control
roup to reduce potential selection bias, there are inherent
imitations about using the historical control. Because of
hanges over time in risks and concomitant medical treat-Figure 2. Kaplan-Meier Survival Curves
Kaplan-Meier survival curves of (A) all-cause mortality, (B) death or myocar-ent, there may be a risk of bias due to systematic
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501Table 4. Baseline Characteristics of Patients Continuing and Not Continuing Clopidogrel at Time of Last Follow-Up After 12 Months
Variable
Continuing Clopidogrel
(n  467)
Not Continuing Clopidogrel
(n  2,384) p Value
Age (yrs) 61.6 10.3 60.4 10.3 0.02
Male 343 (73.4) 1,671 (70.1) 0.15
Diabetes mellitus 143 (30.6) 618 (25.9) 0.04
Hypertension 256 (54.8) 1,196 (50.2) 0.07
Current smoker 118 (25.3) 715 (30.0) 0.04
Hypercholesterolemia 92 (19.7) 579 (24.3) 0.03
Previous myocardial infarction 48 (10.3) 204 (8.6) 0.23
Previous coronary angioplasty 96 (20.6) 383 (16.1) 0.02
Previous coronary artery bypass graft 25 (5.4) 52 (2.2) 0.001
Renal failure 20 (4.3) 45 (1.9) 0.002
Acute coronary syndrome 263 (56.3) 1,208 (50.7) 0.03
Multivessel disease 295 (63.2) 1,350 (56.6) 0.01
Left ventricular ejection fraction (%) 58.3 8.6 58.7 8.8 0.49
Duration of clopidogrel use (months) 22.4 7.9 9.1 5.0 0.001
Lesion characteristics
Left anterior descending artery 232 (49.7) 1,349 (56.6) 0.01
Left main coronary artery 47 (10.1) 187 (7.8) 0.11
ACC/AHA type B2 or C lesion 359 (76.9) 1,876 (78.7) 0.38
Bifurcation lesion 93 (19.9) 461 (19.3) 0.77
Restenotic lesion 32 (6.9) 165 (6.9) 0.96
Ostial lesion 64 (13.7) 236 (9.9) 0.01
Chronic total occlusion 28 (6.0) 161 (6.8) 0.55
Procedural characteristics
Direct stenting without pre-dilation 53 (11.3) 291 (12.2) 0.60
Intervention with intravascular ultrasound guidance 305 (65.3) 1,670 (70.1) 0.04
Number of stents per patient 2.0 1.2 1.9 1.1 0.01
Total stent length per patient (mm) 51.8 32.1 46.9 30.3 0.002
Average stent diameter per patient (mm) 3.2 0.5 3.2 0.7 0.49
Glycoprotein IIb/IIIa inhibitors 30 (6.4) 40 (1.7) 0.001
Data are mean SD or n (%).Abbreviations as in Table 1.Table 5. Unadjusted and Adjusted Hazard Ratios of Stent Thrombosis and Clinical Events Among Patients Continuing and Not Continuing Clopidogrel at
Time of Last Follow-Up After 12 Months
Crude Multivariable Adjusted* Adjusted for Propensity
Outcome
Hazard Ratio
(95% CI) p Value
Hazard Ratio
(95% CI) p Value
Hazard Ratio
(95% CI) p Value
Stent thrombosis
Deﬁnite 0.86 (0.11–6.86) 0.89 1.41 (0.17–11.97) 0.75 1.38 (0.17–11.21) 0.77
Deﬁnite or probable 0.62 (0.15–2.65) 0.56 0.52 (0.06–4.23) 0.54 0.54 (0.07–4.23) 0.55
Any ARC criteria 0.55 (0.07–4.22) 0.52 0.45 (0.10–1.97) 0.29 0.45 (0.10–1.97) 0.29
Clinical events
Death 1.62 (0.75–3.47) 0.22 1.23 (0.56–2.70) 0.61 1.20 (0.55–2.66) 0.65
MI 0.52 (0.07–3.98) 0.53 0.55 (0.07–4.34) 0.57 0.53 (0.07–4.11) 0.54
Death or MI 1.40 (0.68–2.85) 0.36 1.16 (0.56–2.42) 0.69 1.16 (0.56–2.42) 0.69
Cardiac death or MI 0.55 (0.13–2.30) 0.41 0.41 (0.10–1.79) 0.24 0.41 (0.10–1.79) 0.24
*Adjusted for all variables listed in Table 4.Abbreviations as in Tables 2 and 3.
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502ifferences between the groups. To reduce any baseline
ifferences or confounding factors, we performed propensity
nalysis to more rigorously adjust for these biases. None-
heless, observational studies may fail to identify all con-
ounders, and propensity analyses cannot account for selec-
ion bias related to unmeasured characteristics (36).
onclusions
ur study suggests that, compared with BMS, DES was
ssociated with a similar risk of overall ST, but increased rates
f very late ST. Patients with DES had significantly better
isk-adjusted clinical outcomes for death, death or MI, and
arget lesion revascularization. An obvious relationship be-
ween late-occurring (1 year) events and clopidogrel contin-
ation beyond 1 year was not found. Further studies are
equired to determine the long-term safety of DES and the
mpact on late ST of the extended use of clopidogrel.
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